PARENT CONFIDENCE IN EFFICACY AND SAFETY OF ATOPIC DERMATITIS TREATMENT IN CHILDREN. COMPARISON OF ACTIVATED ZINC PYRITHIONE WITH OTHER EXTERNAL THERAPY OPTIONS AS PART OF STEP-BY-STEP APPROACH

The article provides results of a study to assess the satisfaction of the parents with the therapy being administered to children at ages 1 to 6 with moderate atopic dermatitis (objective SCORAD 15–40) when using activated zinc pyrithione (ZP) and any other external agents. All the parents were confident in the safety and efficacy of the treatment for their children when activated ZP was administered. They more often described the administered treatment as straightforward and believed they could use the developed plan of action. No additional agents for external therapy were required when activated ZP was administered. 83% of the subjects in the control group were administered topical corticosteroids. Intensity of symptoms and SCORAD index value bear evidence in favour of activated ZP. The safety of the treatment regimes under review was comparable. The study results indicate that the use of activated ZP makes the therapy for medium severe atopic dermatitis in children efficient, straightforward and meeting expectations of the patients’ parents who want to be sure of the treatment safety. Key words: atopic dermatitis, external therapy, activated zinc pyrithione. (Pediatric Pharmacology. – 2010; 7(2):46-51

PARENT CONFIDENCE IN EFFICACY AND SAFETY OF ATOPIC DERMATITIS TREATMENT IN CHILDREN. COMPARISON OF ACTIVATED ZINC PYRITHIONE WITH OTHER EXTERNAL THERAPY OPTIONS AS PART OF STEP-BY-STEP APPROACH

The article provides results of a study to assess the satisfaction of the parents with the therapy being administered to children at ages 1 to 6 with moderate atopic dermatitis (objective SCORAD 15–40) when using activated zinc pyrithione (ZP) and any other external agents. All the parents were confident in the safety and efficacy of the treatment for their children when activated ZP was administered. They more often described the administered treatment as straightforward and believed they could use the developed plan of action. No additional agents for external therapy were required when activated ZP was administered. 83% of the subjects in the control group were administered topical corticosteroids. Intensity of symptoms and SCORAD index value bear evidence in favour of activated ZP. The safety of the treatment regimes under review was comparable. The study results indicate that the use of activated ZP makes the therapy for medium severe atopic dermatitis in children efficient, straightforward and meeting expectations of the patients’ parents who want to be sure of the treatment safety. Key words: atopic dermatitis, external therapy, activated zinc pyrithione. (Pediatric Pharmacology. – 2010; 7(2):46-51

УВЕРЕННОСТЬ РОДИТЕЛЕЙ В ЭФФЕКТИВНОСТИ И БЕЗОПАСНОСТИ ЛЕЧЕНИЯ АТОПИЧЕСКОГО ДЕРМАТИТА У ДЕТЕЙ. СРАВНЕНИЕ АКТИВИРОВАННОГО ПИРИТИОНА ЦИНКА С ДРУГИМИ ВАРИАНТАМИ НАРУЖНОЙ ТЕРАПИИ В РАМКАХ СТУПЕНЧАТОГО ПОДХОДА

The article provides results of a study to assess the satisfaction of the parents with the therapy being administered to children at ages 1 to 6 with moderate atopic dermatitis (objective SCORAD 15–40) when using activated zinc pyrithione (ZP) and any other external agents. All the parents were confident in the safety and efficacy of the treatment for their children when activated ZP was administered. They more often described the administered treatment as straightforward and believed they could use the developed plan of action. No additional agents for external therapy were required when activated ZP was administered. 83% of the subjects in the control group were administered topical corticosteroids. Intensity of symptoms and SCORAD index value bear evidence in favour of activated ZP. The safety of the treatment regimes under review was comparable. The study results indicate that the use of activated ZP makes the therapy for medium severe atopic dermatitis in children efficient, straightforward and meeting expectations of the patients’ parents who want to be sure of the treatment safety. Key words: atopic dermatitis, external therapy, activated zinc pyrithione. (Pediatric Pharmacology. – 2010; 7(2):46-51)В статье представлены результаты исследования удовлетворенности родителей терапией, которую получают дети в возрасте от 1 года до 6 лет со среднетяжелым атопическим дерматитом (объективный SCORAD 15 - 40) при применении активированного пиритиона цинка (ПЦ) и любых других наружных средств. При применении активированного ПЦ все родители были уверены в безопасности и эффективности лечения своих детей. Они чаще характеризовали использовавшийся режим как простой и считали, что смогут самостоятельно пользоваться разработанным планом действий. При применении активированного ПЦ дополнительное назначение средств наружной терапии не потребовалось. В группе сравнения топические кортикостероиды назначались 83% больных. Выраженность симптомов и значение индекса SCORAD свидетельствовали в пользу активированного ПЦ. Безопасность изучавшихся режимов была сопоставимой. Результаты наблюдения свидетельствуют о том, что применение активированного ПЦ делает терапию среднетяжелого атопического дерматита у детей эффективной, простой и отвечающей ожиданиям родителей пациентов, которые хотят быть уверенными в безопасности лечения. Ключевые слова: атопический дерматит, наружная терапия, активированный пиритион цинка. (Педиатрическая фармакология. – 2010; 7(2):46-51